The Public Health Agency of Canada reported Tuesday that a woman in Quebec is the first to experience a blood clot potentially linked to the AstraZeneca covid vaccine, Canada's public health agency said.
The woman reportedly received the COVISHIELD vaccine, the Serum Institute of India's version of the AstraZeneca COVID-19 shot. She is reportedly recovering at home.
Blood clots associated with the AstraZeneca vaccine were first reported in Europe in early March. A statement released by the Public Health Agency of Canada said that "reports of blood clots with low platelets in people vaccinated with the AstraZeneca COVID-19 vaccine are very rare and the report of this case shows that Canada's vaccine safety monitoring system works."
The statement said that Health Canada had been taking action since the first reported clots to ensure that the COVISHIELD vaccine would be safe for the public.
The National Advisory Committee on Immunization recommended on March 29 that the AstraZeneca vaccine not be used in people under 55, who were more susceptible to the rare vaccine associated clots.
The EU announced on April 7 that there was a "possible link" between the vaccine and the clots, but stated that cases were rare and the benefits still outweighed the risks.
The US also announced today that they would be pausing the use of the Johnson and Johnson one step vaccine due to 6 women developing blood clots associated with the shot.